Company / Operating Income
Spero Therapeutics, Inc. Operating Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$73.4M
FY2025
5-year range
-$88.0M / $21.5M
FY2021-FY2025
Trend
-441.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income changed -442% YoY in FY2025, a notable deviation from the 7-year average annual change of -50%.
Based on SEC 10-K filings.
-$73M in FY2025.
Declined from -$42M to -$73M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income decreased 441.5% year-over-year.
- Peak operating income was recorded in FY2024.
- Lowest operating income in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$73.4M | -441.5% |
| FY2024 | $21.5M | +150.9% |
| FY2023 | -$42.2M | +52.0% |
| FY2022 | -$88.0M | -11.2% |
| FY2021 | -$79.1M | -25.1% |
| FY2020 | -$63.2M | -47.7% |
| FY2019 | -$42.8M | -28.9% |
| FY2018 | -$33.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026